Proceedings of the ASTRO-RSNA Oligometastatic Disease Research Workshop.
Biomarkers, Tumor
/ analysis
Combined Modality Therapy
/ methods
Humans
Immunotherapy
Molecular Targeted Therapy
Neoplasm Metastasis
/ diagnostic imaging
Physics
Practice Guidelines as Topic
Radiation Oncology
/ education
Radiopharmaceuticals
Radiosurgery
Radiotherapy
Randomized Controlled Trials as Topic
Research
Societies, Medical
United States
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
01 11 2020
01 11 2020
Historique:
received:
08
05
2020
accepted:
11
05
2020
pubmed:
21
5
2020
medline:
10
4
2021
entrez:
21
5
2020
Statut:
ppublish
Résumé
On June 13 to 14, 2019, the American Society for Radiation Oncology and the Radiological Society of North America convened a workshop on the treatment of oligometastatic disease in Washington, DC. The workshop was initiated for several reasons. First, oligometastatic disease is of increasing academic and community interest and has been identified by the American Society for Radiation Oncology membership as a top research priority. Second, emerging imaging and diagnostic technologies are more readily defining and detecting oligometastatic disease, making contemporary discussion of oligometastatic disease especially relevant. Third, radiosurgery and radiation in general are theorized to be ideal noninvasive therapy for the treatment of oligometastatic disease. Finally, innovations in targeted therapy and immune therapy have the potential to reverse widely disseminating disease into an oligometastatic state. The workshop was organized into 2 keynote addresses, 6 scientific sessions, and 3 group discussions during an end-of-workshop breakout session. New scientific work was presented in the form of 4 oral presentations and a poster session. Workshop participants were charged with attempting to answer 3 critical questions: (1) Can we refine the clinical and biological definitions of oligometastatic disease; (2) how can we better treat oligometastatic disease; and (3) what clinical trials are needed? Here, we present the proceedings of the workshop. The clinical implications of improved treatment of oligometastatic disease are enormous and immediate. Radiation oncology and diagnostic radiology should rightly be at the forefront of the characterization and treatment of oligometastatic disease. Focused effort is required so that we can translate current efforts of large numbers of studies with few patients to larger studies of larger impact.
Identifiants
pubmed: 32434040
pii: S0360-3016(20)31142-1
doi: 10.1016/j.ijrobp.2020.05.018
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Radiopharmaceuticals
0
Types de publication
Congress
Langues
eng
Sous-ensembles de citation
IM
Pagination
539-545Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.